ArticleFood science and biotechnology2016
Molecular structure and anti-proliferative effect of galangin in HCT-116 cells:
Article in Food science and biotechnology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 29 citations in OpenAlex.
- Preparation and Characterization of Propolis-Biopolymer Coatings on Textiles for Topical Applications: Chemical Composition, Bioactivity, and Cytotoxicity Assessment.Molecules (Basel, Switzerland) · 2026Article
- Development of hesperidin loaded lipid-chitosan nanoparticles: physicochemical characterization, molecular docking and ex vivo study.Scientific reports · 2026Article
- Chitosan/Hesperidin Nanoparticles for Sufficient, Compatible, Antioxidant, and Antitumor Drug Delivery Systems.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Unveiling the Antioxidative Potential of Galangin: Complete and Detailed Mechanistic Insights through Density Functional Theory Studies.The Journal of organic chemistry · 2024Article
- Review
- Galangin: A metabolite that suppresses anti-neoplastic activities through modulation of oncogenic targets.Experimental biology and medicine (Maywood, N.J.) · 2022Article
- Preparation of Iron Oxide and Titania-Based Composite, Core-Shell Populated, Nanoparticulates Material by Two-Step LASER Ablation in Aqueous Media as Antimicrobial and Anticancer Agents.Bioinorganic chemistry and applications · 2022Article
- Article
- Layer-by-Layer Nanoparticles of Tamoxifen and Resveratrol for Dual Drug Delivery System and Potential Triple-Negative Breast Cancer Treatment.Pharmaceutics · 2021Article
- Linalool-Loaded Glutathione-Modified Gold Nanoparticles Conjugated with CALNN Peptide as Apoptosis Inducer and NF-κB Translocation Inhibitor in SKOV-3 Cell Line.International journal of nanomedicine · 2020Article
- Lead Phytochemicals for Anticancer Drug Development.Frontiers in plant science · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Galangin is a naturally occurring plant flavonoid with potential anticancer activity. In present work, the Becke three-parameter hybrid exchange functional method and the Lee-Yang-Parr correction functional methods were used to investigate the structural properties of galangin. The structure-activity relationship analysis has been performed to determine its antioxidant pharmacophore by using density functional theory method and quantum chemical calculations. The free radical scavenging activities of galangin were analyzed with the use of 2, 2-diphenyl-1-picrylhydrazyl and compared with Vitamin C as a control. Galangin decreased the cell proliferation rate in HCT-116 cells and showed concentration- and time-dependent response. Galangin significantly increase the inhibitory effect on HCT-116 clonogenicity and promotes cell cycle arrest at the G2/M or G1 phase, as confirmed by flow cytometry analysis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.